Page 1

THERAPEUTICS Interim report January - March 2021 Patient recruitment in the pivotal study with Emcitate progressing according to plan January March • • Quarterly net sales MSEK 3.8 ( 11.7 ) Quarterly result MSEK -19.3 ( -42.8 ) Cash and cash equivalents MSEK 249.8 ( 221.1 ) • Cash flow for the period MSEK - 38.4 ( -37.2 ) Loss per share before / after dilution SEK -0.1 ( -0.8 ) Significant events during the period January - March • • The company has appointed Kristina Sjöblom Nygren , MD , as CMO , effective May 1 , and will be member of the company's leadership team . The recruitment expands the orphan drug experience and expertise also to the clinical and medical function , further strengthening the company's alignment and strategic focus on this segment . Dr Thomas Lönngren was nominated as new Chairman of the Board at Egetis Therapeutics . Mats Blom was nominated as new board member at Egetis Therapeutics . Emcitate • • Patient recruitment in the pivotal Phase IIb / III early intervention study with the drug candidate Emcitate progresses according to plan . Patient recruitment is expected to be completed in Q4 2021 . Increased interest in the opportunity to treat MCT8 deficiency with Emcitate from physicians across the globe . Emcitate is supplied on a named patient basis in several countries , following special approval from the national regulatory authority with more than 100 MCT8 patients already getting access to Emcitate treatment . Aladote An ODD application has been submitted to the European Medicines Agency ( EMA ) . Preparation for the pivotal Phase IIb / III study for Aladote continues targeting study start in H2 2021 , pending the COVID - 19 pandemic situation . Aladote was presented as a novel emerging treatment of paracetamol overdose at the annual meeting of the Society of Toxicology ( SOT ) on March 16 under the heading Novel Emerging Treatments for Acetaminophen Toxicity . PledOx® No events to report . Significant events after the reporting period Aladote was presented at the scientific meeting of the American College of Medical Toxicology ( ACMT ) on April 14 , under the heading Antidote Updates . The company has parked further Pled Ox development following the POLAR results . Our partner Solasia Pharma KK will continue the pre- clinical program in taxane induced peripheral neuropathy . Egetis Therapeutics appoints Yilmaz Mahshid , PhD as new CFO . Egetis Therapeutics interim report January - March 2021 1